• Explore /
  • Poster
  • / WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.

WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.

Abstract Poster

Authors

null

Toshimi Takano

Toranomon Hospital, Tokyo, Japan

Toshimi Takano , Hideharu Kimura , Kazuto Nishio , Takeharu Yamanaka , Yoshinori Ito , Junya Fukuoka , Junji Tsurutani , Yasushi Shigeoka , Masahiro Uehara , Kazuhiko Sato , Shinichiro Nakamura , Yoichi Nakanishi , Toshiaki Saeki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

UMIN000005219

Citation

J Clin Oncol 30, 2012 (suppl; abstr TPS659)

DOI

10.1200/jco.2012.30.15_suppl.tps659

Abstract #

TPS659

Poster Bd #

16F

Abstract Disclosures

Similar Posters

First Author: Lee S. Schwartzberg

First Author: Min Yan

First Author: Zefei Jiang

First Author: Hope S. Rugo